|
|
|
| Mainly immune phenotype of gastrointestinal stromal tumor and its correlation with risk grading and prognosis |
| GUO Yingxue1 JIA Jianbin1 NIE Shuangfa2 LI Lei2 WANG Tao2 FEI Jiandong2▲ |
1.Graduate School, Hebei North University, Hebei Province, Zhangjiakou 075000, China;
2.Department of Gastroenterological Surgery, the First Affiliated Hospital of Hebei North University, Hebei Province, Zhangjiakou 075000, China |
|
|
|
Abstract Objective To analyze gastrointestinal stromal tumors (GIST) immunophenotype and its relationship with risk classification and prognosis. Methods From April 2015 to April 2017, in the First Affiliated Hospital of Hebei North University, 65 GIST patients were selected. The tissue paraffin section were dealed with SABC method, the expression of CD34, CD117, SMA, DOG1, Ki-67, S-100 and Desmin were analyzed, patients were given follow-up. Results The positive rates of CD117, DOG1, S-100 and Desmin were 96.9%, 100.0%, 6.2% and 4.6%, respectively; the positive rates of CD34, SMA and Ki-67 were 89.2%, 29.2% and 29.2% respectively; the positive expression of CD34 was not correlated with mitotic phase, risk grade and tumor size (P > 0.05); the positive expression of SMA was not correlated with mitotic phase, risk phase and tumor size (P > 0.05); Ki-67 expression was positively correlated with mitotic number, risk grade and tumor size (r = 0.715, 0.418, 0.397, P < 0.05); Ki-67 positive recurrence rate was 36.4%, mortality rate was 27.3%, and Ki-67 negative recurrence rate was 6.9%, the mortality rate was 3.4%, and the differences between the two groups were statistically significant (P < 0.05). Conclusion When diagnosing GIST, it can be combined with CD34, CD117 and DOG1, which have better complementarity. Detecting the levels of SMA, S-100 and Desmin protein can improve the accuracy of clinical diagnosis. Combined with Ki-67 factors, the prognosis of patients with GIST can be evaluated effectively.
|
|
|
|
|
|
[1] 杜娟，王彦荣，宋彬，等.胃肠道间质瘤免疫表型的表达及临床意义[J].现代肿瘤医学，2015，23（10）：1389-1392.
[2] Kanda T. Criminal or bystander：imatinib and second primary malignancy in GIST patients [J].中国癌症研究：英文版，2013，25（5）：490-492.
[3] 蹇顺海，文彬，黄一凡，等.胃肠道间质瘤新版风险分级方案的应用与评价[J].中国肿瘤临床，2011，38（14）：859-862.
[4] 陶丽莹，刘冰熔.胃肠道间质瘤治疗策略的研究进展[J].胃肠病学和肝病学杂志，2017，26（2）：214-217.
[5] 李峰.多层螺旋CT对老年胃肠道间质瘤患者的诊断价值[J].中华老年多器官疾病杂志，2017，16（7）：512-515.
[6] 李辛辛，林思彤，罗元，等.胃肠间质瘤伴发其他原发癌的病理及DOG-1、P16表达分析[J].广西医学，2015，17（4）：543-546.
[7] 赵传华，徐建明.胃肠间质瘤的治疗进展[J].临床肿瘤学杂志，2014，33（5）：465-468.
[8] 王富强，谭改民.29例上皮样胃肠间质瘤的临床病理特征[J].临床与病理杂志，2017，37（3）：451-455.
[9] Revheim ME，Kristian A，Malinen E，et al. Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H [J]. Acta Oncol，2013，52（4）：776-782.
[10] 谢天.ER81在GIST中的表达与临床病理因素及CD117、ki-67的相关性[D].郑州：郑州大学，2012.
[11] 李胜水，张凤梅，李秀清，等.ILK，Ki-67在胃肠间质瘤中的表达及其意义[J].医学信息，2013，14（21）：158-158.
[12] 林文生，张芳，任力，等.胃肠间质瘤合并消化道癌9例临床病理分析[J].临床与实验病理学杂志，2017，33（6）：613-617.
[13] 殷蓓琦，黄秋芳.三种不同免疫检测法对乙肝血清学标志物检测的结果对比分析[J].标记免疫分析与临床，2017， 24（6）：682-685.
[14] 马少君，刘延梅，梁晓燕，等.胃间质瘤的CT表现及生物学评价相关性分析[J].临床消化病杂志，2017，29（1）：22-26.
[15] 李健.胃肠间质瘤诊治的发展历程与方向[J].中国普外基础与临床杂志，2017，24（2）：137-140.
[16] ■ahin S，Ekinci ?魻，Se?觭kin S，et al. The diagnostic and prognostic utility of DOG1 expression on gastrointestinal stromal tumors [J]. Turk Patoloji Derg，2017，33（1）：1.
[17] 许春伟，韩鸿雁，王晶晶，等.CD117、PDGFRA蛋白单独及联合DOG1检测在胃肠道间质瘤中的诊断价值[J].临床与病理杂志，2015，35（2）：252-257.
[18] 陈水姣，卢放根.DOG1的表达和功能及其在GIST鉴别诊断中的意义[J].医学与哲学，2012，33（18）：39-41.
[19] Ricci R，DeiTos AP，Rindi G，et al. GISTogram：a graphic presentation of the growing GIST complexity [J]. J Pathol，2013，463（4）：481-487.
[20] 展瑞.胃腺癌中P53、HER2和Ki-67的表达及相关分析[J].中国当代医药，2016，23（27）：153-155.
[21] 王帆荣，陈芸，李梅，等.胃肠道间质瘤中Ki-67表达及其与临床病理特征、危险度分级的相关性[J].临床与实验病理学杂志，2017，33（9）：1022-1025. |
|
|
|
